In a controlled seven week stndy in ten patients with chronic obstructive bronchitis, nebnlized N-acetylcysteine combined with racemic epinephrine was highly effective in thinning sputum. By contrast, nebulized saline plus racemic epinephrine tended to make the sputum thicker in these same patients. Neither the N-acetylcysteine-racemic epinephrine combition nor the salineracemic epinephrine aerosol exhibited any observable effect on the chest roentgenogram, spirometric measurements or sputum vohme in this group of patients. The bronchial obstruction previously observed with N-acetylcysteine alone did not occur when the drug was nebulized with racemic epinepbrine. We would conchde that whenever N-acetylcysteine is administered, a bronchodilator should be nebulized concomitantly less there is a clear contraindication to its use. N-acetylcysteine (Mucomyst) has been reported to be an effective mucolytic agent both in vitrol and during short term administration to patients.*," Nebulized N-acetylcysteine has been used successfully for prevention and treatment of postoperative pulmonary complications,2 for short periods on patients with chronic bronchial disease4 and for patients with cystic fibrosis.Wost previous studies have evaluated patients before and after a single administration of N-acetyl~ysteine~~~ and not in a well-controlled continuing therapeutic regimen.
N-acetylcysteine (Mucomyst) has been reported to be an effective mucolytic agent both in vitrol and during short term administration to patients.*," Nebulized N-acetylcysteine has been used successfully for prevention and treatment of postoperative pulmonary complications,2 for short periods on patients with chronic bronchial disease4 and for patients with cystic fibrosis.Wost previous studies have evaluated patients before and after a single administration of N-acetyl~ysteine~~~ and not in a well-controlled continuing therapeutic regimen.
The major diEculty in the study of these expectorant agents is the problems of obtaining an objective measurement of their effectiveness. With this in mind we have developed an instrument which provides an accurate and reproducible measurement of sputum consisten~y.~.~ We use the term consistency instead of viscosity because the latter term can be properly applied only to homogeneous fluids and sputum is obviously heterogeneous. The "sputum consistometer" does provide a reliable assessment of "thickness* or "thinness" of sputum which, in turn, permits an objective evaluation of expectorant and &ucolytic drugs. One of the side-effects encountered in the use of N-acetylcysteine is bronchial obstruction, particularly in those patients with bronchospastic disease. Bernstein and Ausdenmore8 found that this effect could be prevented by the concomitant adrninstration of a bronchodilator agent, but they did not determine whether the bronchodilator altered the mucolytic effect of N-acetylcysteine (N-ac).
The present study was designed to evaluate under as controlled conditions as possible: ( a ) whether mucolytic effectiveness was retained when N-acetylcysteink was administered by aerosol in combination with a bronchodilator agent, and ( b ) whether nebulization of a bronchodilator-N-acetylcysteine combination three times daily is effective in thinning sputum and improving ventilatory function when administered in a continuing therapeutic program. In order to achieve controlled conditions for this study, patients with reasonably stable, but persistent, chronic productive bronchitis seemed best suited to demonstrate such changes.
Wood Veterans Administration Hospital. All patients manifested some degree of airway obstruction in addition to chronic productive cough, but the disease process in each was as stable clinically as could be achieved by conventional therapy. Table 1 lists the ages, the diagnoses, and the clinical features of each patient.
Before entering the study each patient was given an appropriate therapeutic regimen including oral broncbodilators, expectorants, and in some cases, antibiotics. This regimen, once established, was maintained with little or no change throughout the study.
The therapeutic testing program was designed to compare the effects of nebulization of N-aoetylcysteine combined with racemic epinephrine both with control periods and with nebulization of saline plus racemic epinephrine. Racemic epinephrine was selected in order to avoid possible tachyphylaxis to isoproterenol since most of the patients had been receiving this drug as a part of their previous therapy. In order to lessen any errors introduced by the natural fluctuations of the disease, the patients were divided into two groups. The first week of the study was a control week for both groups and, as in the subsequent control periods, no nebulization was given. During the second week, the patients in group A received the combination of saline plus racemic epinephrine (S + RE) while those in group B received N-acetylcysteine plus racemic epinephrine (N-ac + RE). During the third week, the group A patients received N-ac + RE and those in group B, S + RE. The fourth week was a control period in both groups. During the fifth and sixth weeks N-ac + RE and S + RE were given to each group with the order of administration of the drugs reversed from that used during the second and third weeks. The seventh week was the third control period. Table 2 summarizes the plan of sh~dy.
Racemic epinephrine dosage was 2.0 mg (12 drops of a 2.25 per cent solution) added to 3.5 ml of either normal saline or 20 per cent N-acetylcysteine. AU nebulization was clone with a Mark VII Bird IPPB respirator. The patients were evaluated clinically each day, and subjective sideeffects of the nebulization therapy were assessed. Chest roentgenograms were taken before the test periods and at the end of each week throughout the test and control periods. Spirometric testing was done in the midafternoon of each Monday, Wednesday and Friday of the entire study and at least three hours after the preceding nebulization in order to avoid the acute bronchodilating effect of RE. The spirometric testing consisted of measurement of the forced vital capacity (FVC), the one second forced expiratory volume (FEV,,,) , the U) O-1, 2€10 ml forced expiratory flow (FEF200-1,200 ) and the forced mid-flow (FMF) as defined by Kory, Rankin and Snider.9 The seven minute nitrogen washout test as described by Baldwin, Cournand and Richards10 was performed initially and weekly throughout the entire study.
All sputum was collected throughout the entire study for measurement of volume and consistency with our sputum consistometer. Each specimen was frozen immediately after collection and later thawed for the volume and consistency determinations. Previous studies in our laboratory have shown that sputum volume and consistency were not affected by a single Freezing and thawing. Sputum was collected in three periods throughout the day; the first specimen (morning) from 8 A M until 1 PM, the second specimen (afternoon) from 1 P M until 6 PM, and the third specimen (overnight) from 6 PM until 8 A M the following morning.
The sputum consistometer developed by us measures the consistency of an entire specimen of sputum in terms of shearing force. The basic part of the unit is a 10 ml stainless steel syringe with a hollow plunger carefully machined to fit the syringe barrel. At the lower end of the plunger is a stainless steel disc, 1/32-inch thick, which is held in place against the bottom of the plunger by a thin rod. This rod extends up through the hollow plunger and is secured by a knurled nut. This disc contains eight symmetrically arranged holes, each 1.6 mm in diameter. The bottom end of the syringe barrel is threaded so that a Statham P-23D strain gauge pressure transducer may be secured tightly in place with the aid of O-ring seals. Figure 1 is a diagram of the modified syringe assembly. The sputum consistometer as previously described by us? has been d e d and improved. The sputum is placed in the syringe barrel which is mounted on a modified Harvard infusion pump. The pump drives the plunger at a constant velocity (4.12 ml/min) through the column of sputum contained in the syringe barrel thereby developing a pressure directly proportional to the thickness (consistency) of the sputum. In our previous reports9. 7 we have axpressed the sputum consistency in terms of the mean pressure in millimeters of mercury produced as the plunger was driven through the column of sputum. Recently we have found it m r e . meaningful to relate our consistency values to viscosity , units in general use. In order to accomplish this we have The overall summary of the data from the more than 1,400 sputum consistency values for these ten patients is graphically shown in Figure 5 . For clarity of presentation Figure 5 was constructed without reference to the order of administration of the drugs. It is evident from this figure that the mean sputum consistency values for all N-ac + RE periods are lower than any of the control periods or the S + RE periods. By contrast the sputum consistency for each S + RE period is higher than either the control values or N-ac + RE except for the overnight specimens. The data summarized in Figure 5 were subjected to analysis of variance which showed the following: (a) There was An even more striking demonstration of these effects is shown by Figure 6 in which the number of drug tials for the ten patients were plotted to show how many weekly mean consistency values for the test periods were either thicker, thinner or in between the values for their corresponding control periods. It is apparent that in 20 out of 20 trials (two tials in each of ten patients) the sputum during the N-ac + RE period was thinner than either control period, both for the morning and afternoon specimens. By contrast, the saline + RE sputums were thicker than both controls in ten of 20 trials for the morning specimens and in 11 of 20 for the afternoon specimens. As might be expected, the overnight specimens for both N-ac + RE and S + RE showed less striking results. Figure 7 is a bar graph which illustrates the weekly mean values for sputum volume in a manner similar to Figure 5 . It is apparent that the sputum volumes do not show striking differences between control, N-ac + RE or S + RE periods. Analysis of variance reveals no significant differences between any of the seven periods. It can be seen that the mean values for the three control periods decreased progressively but these decreases are not statistically significant.
None of the spirometric measurements (FVC, FEV1.0, FEF200.120c,, and FMF) was appreciably affected by nebulization of N-ac + RE or S + RE.
The seven minute nitrogen washout test showed such great variability that no conclusions could be drawn from the performance of this test.
There were no changes in the chest roentgenograms which could be associated with any of the treatment regimens.
DISCUSSION Although a number of clinical reports have attested to the efficacy of nebulized N-acetylcysteine,2~"'.~ no well-controlled clinical studies of this agent have been reported in which it was administered in a continuing therapeutic program. Our previous studies showed that nebulized single ad- ministrations of N-ac were effective in reducing sputum consistency as compared to similarly administered single doses of saline. The occurrence of bronchial obstructive side-effects in our previous study8 and in that of Bernstein and Ausdenmore8 further suggested that nebulization of N-ac combined with a bronchodilating agent should also be evaluated.
This clinical study not only confirms Scheher's in vitro work1 and our previous reportssv7 on the effectiveness of N-ac as mucolytic agent, but also shows that N-ac may be used together with racemic epinephrine with no loss of effectiveness. The more pronounced effect of N-ac + RE on the morning and afternoon specimens, as compared to the overnight specimen, is not unexpected since the overnight sputum specimens encompassed a period of 14 hours following the evening treatment and much of the collection time was beyond the period of effectiveness for the agents. In contrast, the moming and afternoon sputum collections represented only a five hour period following the previous nebulization.
Each patient was chosen for this study because of his relatively stable clinical course. These patients, therefore, were able to provide reliable control periods with which the drug regimens could be compared. These patients were not chosen because of their need for mucolytic therapy although they did have thick sputum. Patients who have a more acute need for mucolytic agents (in such diseases as laryngotracheobronchitis, acute bronchitis, and postoperative plugging bronchi with mucus) often are so seriously ill, have such wide fluctuations in their course, and require so many other simultaneous therapeutic measures that it becomes almost impossible to evaluate mucolytic agents objectively. Nevertheless, it seems quite reasonable to expect that the sputum thinning ability of N-acetylcysteine so clearly demonstrated in the present study is just as applicable to acutely ill patients with thick, tenacious sputum.
The inability of these agents to improve the ventilatory studies and the chest roentgenograms in our patients with stable chronic bronchitis confirms the findings of Moser and Rhodese that single N-ac nebulizations did not improve pulmonary ventilation. These results do not mean that the drugs are ineffective but suggest that in our patients irreversible tissue changes are more responsible for ventilatory impairment than is obstruction of the airway by secretions.
One of the more interesting observations in this study was the inability of the patients to differentiate between the effects of S + RE and N-ac + RE in terms of ease of breathing or the ability to raise sputum. The symptomatic improvement with either regimen points to the difficulty in comparing drug efficacy by subjective criteria.
